NEW YORK, Nov. 18, 2016 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Endo International plc ("Endo" or the "Company") (NASDAQ: ENDP) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 16-cv-08645, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Endo securities between September 28, 2015 and November 2, 2016, both dates inclusive (the "Class Period"), seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934. If you are a shareholder who purchased Endo securities during the Class Period, you have until January 6, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at firstname.lastname@example.org or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. [Click here to join this class action] Endo develops, manufactures, and distributes pharmaceutical products and devices worldwide. The Company's U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. Endo sells its branded pharmaceuticals and generics directly, as well as through wholesale drug distributors. On September 28, 2015, Endo announced that it had completed its $8.05 billion acquisition of Par Pharmaceutical Holdings, Inc. ("Par Pharmaceutical") from the private investment firm TPG. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Endo's subsidiary, Par Pharmaceutical, had colluded with several of its industry peers to fix generic drug prices; (ii) the foregoing conduct constituted a violation of federal antitrust laws; (iii) consequently, Endo's revenues during the Class Period were in part the result of illegal conduct; and (iv) as a result of the foregoing, Endo's public statements were materially false and misleading at all relevant times.